By proceeding, you agree to our Terms of Use and Privacy Policy.
The current generation of CAR-T approaches for hematological malignancies generate strong responses in cancer patients, but too often progression-free survival is less than 12 months. The next-generation allogeneic approaches may make these therapies more accessible to the patients who need them but have been hampered by poor in vivo persistence.
Explore the current generation of CAR-T approaches for hematological malignancies to generate strong responses in cancer patients.
Speakers from AbbVie, Arcellx, Editas Medicine & more will discuss enhancing NK cells through gene editing and talk on alternative cell types.
Networking will provide you with a clear understanding on challenges like Immunosuppressive Microenvironment and a strong ability for tumor antigen escape.
Kisaco Research works with the early adopters and leaders of growth markets in driving their respective industries forward and in providing the right knowledge, learning and social opportunities to stimulate business growth quickly and effectively.
Elicera Therapeutics is a clinical stage cell and gene therapy company focusing on immunooncology.
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.